J. Gamble

First name
J.
Middle name
M.
Last name
Gamble
Alkabbani, W., Shah, B. R., Zongo, A., Eurich, D. T., Alsabbagh, M. W., & Gamble, J. M. (2023). Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15241
View
Amegadzie, J. E., Gamble, J. M., Farrell, J., & Gao, Z. (2022). Association between Inhaled β(2)-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study. Int J Chron Obstruct Pulmon Dis, 17, 1205-1217. http://doi.org/10.2147/copd.s358927
View
Alkabbani, W., Zongo, A., Minhas-Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. M. (2022). Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus. Diabet Med, e14858. http://doi.org/10.1111/dme.14858
View
Alkabbani, W., Zongo, A., Minhas-Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. M. (2021). Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study. Can J Diabetes. http://doi.org/10.1016/j.jcjd.2021.12.005
View
Gamble, J. M., Thomas, J. M., Twells, L. K., Midodzi, W. K., & Majumdar, S. R. (2016). Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users. Medicine (Baltimore). http://doi.org/10.1097/md.0000000000003995
View
Gamble, J. M., Chibrikov, E., Twells, L. K., Midodzi, W. K., Young, S. W., MacDonald, D., & Majumdar, S. R. (2017). Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol. http://doi.org/10.1016/s2213-8587(16)30316-3
View
Gamble, J. M., Donnan, J. R., Chibrikov, E., Twells, L. K., Midodzi, W. K., & Majumdar, S. R. (2018). The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study. Diabetes Res Clin Pract. http://doi.org/10.1016/j.diabres.2017.12.008
View
Gamble, J. M., Chibrikov, E., Midodzi, W. K., Twells, L. K., & Majumdar, S. R. (2018). Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink. BMJ Open. http://doi.org/10.1136/bmjopen-2018-023830
View
Gamble, J. M., Donnan, J. R., Chibrikov, E., Twells, L. K., Midodzi, W. K., & Majumdar, S. R. (2018). Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes. Sci Rep. http://doi.org/10.1038/s41598-018-33483-y
View
Amegadzie, J. E., Badejo, O., Gamble, J. M., Wright, M., Farrell, J., Jackson, B., et al. (2019). Validated methods to identify patients with asthma-COPD overlap in healthcare databases: a systematic review protocol. BMJ Open. http://doi.org/10.1136/bmjopen-2018-024306
View